{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:38:12Z","timestamp":1790260692817,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T00:00:00Z","timestamp":1364860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/nrneph.2013.59","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T11:26:38Z","timestamp":1364901998000},"page":"320-327","source":"Crossref","is-referenced-by-count":77,"title":["Treatment of IgA nephropathy and Henoch\u2013Sch\u00f6nlein nephritis"],"prefix":"10.1038","volume":"9","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Feehally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,2]]},"reference":[{"key":"BFnrneph201359_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan, A., Franssen, C. F. & de Vries, C. S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol. Dial. Transplant. 26, 414\u2013430 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-med-041811-142014","volume":"64","author":"K Kiryluk","year":"2013","unstructured":"Kiryluk, K., Novak, J. & Gharavi, A. G. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu. Rev. Med. 64, 339\u2013356 (2013).","journal-title":"Annu. Rev. Med."},{"key":"BFnrneph201359_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/j.ajkd.2011.03.024","volume":"58","author":"J Feehally","year":"2011","unstructured":"Feehally, J. & Cameron, J. S. IgA nephropathy: progress before and since Berger. Am. J. Kidney Dis. 58, 310\u2013319 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","volume":"28","author":"S Pouria","year":"2008","unstructured":"Pouria, S. & Barratt, J. Secondary IgA nephropathy. Semin. Nephrol. 28, 27\u201337 (2008).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201359_CR5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1523-1755.2004.00833.x","volume":"66","author":"F Rivera","year":"2004","unstructured":"Rivera, F., Lopez-Gomez, J. M. & Perez-Garcia, R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 66, 898\u2013904 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/ndt\/4.11.943","volume":"4","author":"R Waldherr","year":"1989","unstructured":"Waldherr, R., Rambausek, M., Duncker, W. D. & Ritz, E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol. Dial. Transplant. 4, 943\u2013946 (1989).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR7","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","volume":"63","author":"K Suzuki","year":"2003","unstructured":"Suzuki, K. et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 63, 2286\u20132294 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR8","first-page":"160","volume":"33","author":"N Yoshikawa","year":"1990","unstructured":"Yoshikawa, N. et al. Repeat renal biopsy in children with IgA nephropathy. Clin. Nephrol. 33, 160\u2013167 (1990).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201359_CR9","first-page":"2208","volume":"19","author":"X Cuevas","year":"1987","unstructured":"Cuevas, X., Lloveras, J., Mir, M., Aubia, J. & Masramon, J. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant. Proc. 19, 2208\u20132209 (1987).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201359_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1681\/ASN.2012010063","volume":"23","author":"E Gutierrez","year":"2012","unstructured":"Gutierrez, E. et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J. Am. Soc. Nephrol. 23, 1753\u20131760 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","volume":"110","author":"CC Szeto","year":"2001","unstructured":"Szeto, C. C. et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am. J. Med. 110, 434\u2013437 (2001).","journal-title":"Am. J. Med."},{"key":"BFnrneph201359_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","volume":"39","author":"O Hotta","year":"2002","unstructured":"Hotta, O., Furuta, T., Chiba, S., Tomioka, S. & Taguma, Y. Regression of IgA nephropathy: a repeat biopsy study. Am. J. Kidney Dis. 39, 493\u2013502 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","volume":"8","author":"MG Radford Jr","year":"1997","unstructured":"Radford, M. G. Jr, Donadio, J. V. Jr, Bergstralh, E. J. & Grande, J. P. Predicting renal outcome in IgA nephropathy. J. Am. Soc. Nephrol. 8, 199\u2013207 (1997).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR14","first-page":"363","volume":"59","author":"G D'Amico","year":"1986","unstructured":"D'Amico, G. et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q. J. Med. 59, 363\u2013378 (1986).","journal-title":"Q. J. Med."},{"key":"BFnrneph201359_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1681\/ASN.2010040355","volume":"22","author":"F Berthoux","year":"2011","unstructured":"Berthoux, F. et al. Predicting the risk for dialysis or death in IgA nephropathy. J. Am. Soc. Nephrol. 22, 752\u2013761 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR16","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich, H. N., Troyanov, S., Scholey, J. W. & Cattran, D. C. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 18, 3177\u20133183 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le, W. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 27, 1479\u20131485 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0272-6386(01)80120-7","volume":"37","author":"F Bonnet","year":"2001","unstructured":"Bonnet, F. et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am. J. Kidney Dis. 37, 720\u2013727 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.ajkd.2010.02.351","volume":"56","author":"R Yamamoto","year":"2010","unstructured":"Yamamoto, R. et al. Cigarette smoking and progression of IgA nephropathy. Am. J. Kidney Dis. 56, 313\u2013324 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran, D. C. et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534\u2013545 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ki.2011.126","volume":"80","author":"AM Herzenberg","year":"2011","unstructured":"Herzenberg, A. M. et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 80, 310\u2013317 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.ajkd.2012.06.011","volume":"60","author":"CH Zeng","year":"2012","unstructured":"Zeng, C. H. et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult chinese patients. Am. J. Kidney Dis. 60, 812\u2013820 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/ndt\/gfr339","volume":"27","author":"S Edstrom Halling","year":"2012","unstructured":"Edstrom Halling, S., Soderberg, M. P. & Berg, U. B. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol. Dial. Transplant. 27, 715\u2013722 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000332223","volume":"34","author":"T Yau","year":"2011","unstructured":"Yau, T., Korbet, S. M., Schwartz, M. M. & Cimbaluk, D. J. The Oxford classification of IgA nephropathy: a retrospective analysis. Am. J. Nephrol. 34, 435\u2013444 (2011).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201359_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00467-011-2061-0","volume":"27","author":"Y Shima","year":"2012","unstructured":"Shima, Y. et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr. Nephrol. 27, 783\u2013792 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201359_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/ndt\/gfr295","volume":"27","author":"SH Kang","year":"2012","unstructured":"Kang, S. H. et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol. Dial. Transplant. 27, 252\u2013258 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR27","unstructured":"ERA-EDTA. Advances in the European Validation Study of the Oxford Classification of IgA Nephropathy (VALIGA) [online] , (2011)."},{"key":"BFnrneph201359_CR28","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. Suppl. 2, 139\u2013274 (2012)."},{"key":"BFnrneph201359_CR29","first-page":"337","volume":"49","author":"LJ Vleming","year":"1998","unstructured":"Vleming, L. J. et al. Histomorphometric correlates of renal failure in IgA nephropathy. Clin. Nephrol. 49, 337\u2013344 (1998).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201359_CR30","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.2215\/CJN.01170211","volume":"6","author":"E Alamartine","year":"2011","unstructured":"Alamartine, E. et al. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin. J. Am. Soc. Nephrol. 6, 2384\u20132388 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR31","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/ndt\/gfr554","volume":"27","author":"S Lundberg","year":"2012","unstructured":"Lundberg, S., Lundahl, J., Gunnarsson, I., Sundelin, B. & Jacobson, S. H. Soluble interleukin-2 receptor alfa predicts renal outcome in IgA nephropathy. Nephrol. Dial. Transplant. 27, 1916\u20131923 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.10331011","volume":"7","author":"S Lundberg","year":"2012","unstructured":"Lundberg, S. et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin. J. Am. Soc. Nephrol. 7, 727\u2013734 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/ki.2010.314","volume":"78","author":"MT Vuong","year":"2010","unstructured":"Vuong, M. T. et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int. 78, 1281\u20131287 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR34","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/ki.1996.521","volume":"50","author":"E Ranieri","year":"1996","unstructured":"Ranieri, E., Gesualdo, L., Petrarulo, F. & Schena, F. P. Urinary IL-6\/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 50, 1990\u20132001 (1996).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.ki.5002621","volume":"73","author":"DD Torres","year":"2008","unstructured":"Torres, D. D. et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 73, 327\u2013333 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR36","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/ki.1997.171","volume":"51","author":"J Zwirner","year":"1997","unstructured":"Zwirner, J. et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 51, 1257\u20131264 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0272-6386(00)70296-4","volume":"35","author":"U Janssen","year":"2000","unstructured":"Janssen, U. et al. Activation of the acute phase response and complement C3 in patients with IgA nephropathy. Am. J. Kidney Dis. 35, 21\u201328 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2249.2012.04604.x","volume":"169","author":"LL Liu","year":"2012","unstructured":"Liu, L. L., Jiang, Y., Wang, L. N. & Liu, N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin. Exp. Immunol. 169, 148\u2013155 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph201359_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/pmic.200700492","volume":"8","author":"MT Rocchetti","year":"2008","unstructured":"Rocchetti, M. T. et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 8, 206\u2013216 (2008).","journal-title":"Proteomics"},{"key":"BFnrneph201359_CR40","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/j.1523-1755.2005.00335.x","volume":"67","author":"M Haubitz","year":"2005","unstructured":"Haubitz, M. et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 67, 2313\u20132320 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2010111130","volume":"23","author":"K El Karoui","year":"2012","unstructured":"El Karoui, K. et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J. Am. Soc. Nephrol. 23, 137\u2013148 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR42","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1681\/ASN.2005090923","volume":"17","author":"A Roos","year":"2006","unstructured":"Roos, A. et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 17, 1724\u20131734 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR43","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1093\/ndt\/gfr139","volume":"26","author":"H Kataoka","year":"2011","unstructured":"Kataoka, H., Ohara, M., Honda, K., Mochizuki, T. & Nitta, K. Maximal glomerular diameter as a 10-year prognostic indicator for IgA nephropathy. Nephrol. Dial. Transplant. 26, 3937\u20133943 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR44","first-page":"503","volume":"18","author":"R Coppo","year":"2005","unstructured":"Coppo, R. & D'Amico, G. Factors predicting progression of IgA nephropathies. J. Nephrol. 18, 503\u2013512 (2005).","journal-title":"J. Nephrol."},{"key":"BFnrneph201359_CR45","unstructured":"KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. Suppl. 2, 340\u2013414 (2012)."},{"key":"BFnrneph201359_CR46","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1681\/ASN.2011030221","volume":"22","author":"J Floege","year":"2011","unstructured":"Floege, J. & Eitner, F. Current therapy for IgA nephropathy. J. Am. Soc. Nephrol. 22, 1785\u20131794 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR47","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","volume":"14","author":"WA Wilmer","year":"2003","unstructured":"Wilmer, W. A. et al. Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol. 14, 3217\u20133232 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMcp0906797","volume":"362","author":"H Abboud","year":"2010","unstructured":"Abboud, H. & Henrich, W. L. Clinical practice. Stage IV chronic kidney disease. N. Engl. J. Med. 362, 56\u201365 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201359_CR49","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga, M., Gutierrez, E., Gonzalez, E., Morales, E. & Hernandez, E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 14, 1578\u20131583 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR50","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo, R. et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J. Am. Soc. Nephrol. 18, 1880\u20131888 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li, P. K. et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am. J. Kidney Dis. 47, 751\u2013760 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR52","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1442-200x.2004.01955.x","volume":"46","author":"H Tanaka","year":"2004","unstructured":"Tanaka, H. et al. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr. Int. 46, 576\u2013579 (2004).","journal-title":"Pediatr. Int."},{"key":"BFnrneph201359_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","volume":"38","author":"D Russo","year":"2001","unstructured":"Russo, D. et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am. J. Kidney Dis. 38, 18\u201325 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR54","first-page":"284","volume":"21","author":"F Eitner","year":"2008","unstructured":"Eitner, F., Ackermann, D., Hilgers, R. D. & Floege, J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J. Nephrol. 21, 284\u2013289 (2008).","journal-title":"J. Nephrol."},{"key":"BFnrneph201359_CR55","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrneph201359_CR56","first-page":"285","volume":"52","author":"U Scholl","year":"1999","unstructured":"Scholl, U. et al. The \u201cpoint of no return\u201d and the rate of progression in the natural history of IgA nephritis. Clin. Nephrol. 52, 285\u2013292 (1999).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201359_CR57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000422389","volume":"104","author":"G D'Amico","year":"1993","unstructured":"D'Amico, G., Ragni, A., Gandini, E. & Fellin, G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib. Nephrol. 104, 6\u201313 (1993).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph201359_CR58","first-page":"175","volume":"54","author":"F Ota","year":"2000","unstructured":"Ota, F., Ueki, K., Naruse, T. & Nojima, Y. Patients with IgA nephropathy whose renal function remains stable for a long time even after exceeding the \u201cpoint of no return\u201d. Clin. Nephrol. 54, 175\u2013176 (2000).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201359_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131\u2013140 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201359_CR60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie, F. W. & Roberts, I. S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J. Am. Soc. Nephrol. 13, 142\u2013148 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR61","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/sj.ki.5001875","volume":"70","author":"K Uhlig","year":"2006","unstructured":"Uhlig, K. et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 70, 2058\u20132065 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR62","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi, R. et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am. J. Kidney Dis. 41, 972\u2013983 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2215\/CJN.01020905","volume":"1","author":"RJ Hogg","year":"2006","unstructured":"Hogg, R. J. et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 1, 467\u2013474 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi, C. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J. Am. Soc. Nephrol. 15, 157\u2013163 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR65","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi, C. et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353, 883\u2013887 (1999).","journal-title":"Lancet"},{"key":"BFnrneph201359_CR66","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno, C., Torres, D. D., Rossini, M., Pesce, F. & Schena, F. P. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol. Dial. Transplant. 24, 3694\u20133701 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv, J. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am. J. Kidney Dis. 53, 26\u201332 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201359_CR68","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrneph.2010.31","volume":"6","author":"F Eitner","year":"2010","unstructured":"Eitner, F. & Floege, J. Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? Nat. Rev. Nephrol. 6, 252\u2013254 (2010).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201359_CR69","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1093\/ndt\/gfr212","volume":"26","author":"W Drescher","year":"2011","unstructured":"Drescher, W., Schlieper, G., Floege, J. & Eitner, F. Steroid-related osteonecrosis\u2014an update. Nephrol. Dial. Transplant. 26, 2728\u20132731 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR70","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi, C. et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J. Am. Soc. Nephrol. 21, 1783\u20131790 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201359_CR71","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrneph201359_CR72","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch, G. et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol. Dial. Transplant. 20, 2139\u20132145 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR73","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes, B. D. et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 65, 1842\u20131849 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR74","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2009.499","volume":"77","author":"SC Tang","year":"2010","unstructured":"Tang, S. C. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 77, 543\u2013549 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrneph201359_CR76","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/ndt\/gfn161","volume":"23","author":"J Lv","year":"2008","unstructured":"Lv, J. et al. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol. Dial. Transplant. 23, 2868\u20132872 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR77","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000065281","volume":"22","author":"Z Tang","year":"2002","unstructured":"Tang, Z. et al. Idiopathic IgA nephropathy with diffuse crescent formation. Am. J. Nephrol. 22, 480\u2013486 (2002).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201359_CR78","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","volume":"18","author":"JA Tumlin","year":"2003","unstructured":"Tumlin, J. A., Lohavichan, V. & Hennigar, R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol. Dial. Transplant. 18, 1321\u20131329 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR79","doi-asserted-by":"publisher","first-page":"c16","DOI":"10.1159\/000210570","volume":"112","author":"T Pankhurst","year":"2009","unstructured":"Pankhurst, T. et al. Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin. Pract. 112, c16\u2013c24 (2009).","journal-title":"Nephron Clin. Pract."},{"issue":"Suppl.","key":"BFnrneph201359_CR80","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.3346\/jkms.2009.24.S1.S44","volume":"24","author":"SM Kim","year":"2009","unstructured":"Kim, S. M. et al. Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J. Korean Med. Sci. 24 (Suppl.) S44\u2013S49 (2009).","journal-title":"J. Korean Med. Sci."},{"key":"BFnrneph201359_CR81","first-page":"174","volume":"26","author":"KN Lai","year":"1986","unstructured":"Lai, K. N., Lai, F. M., Ho, C. P. & Chan, K. W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin. Nephrol. 26, 174\u2013180 (1986).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201359_CR82","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.2012.302","volume":"82","author":"HJ Oh","year":"2012","unstructured":"Oh, H. J. et al. Clinical outcomes, when matched at presentation, do not vary between adult-onset Henoch-Sch\u00f6nlein purpura nephritis and IgA nephropathy. Kidney Int. 82, 1304\u20131312 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR83","doi-asserted-by":"publisher","unstructured":"Chartapisak, W., Opastirakul, S., Hodson, E. M., Willis, N. S. & Craig, J. C. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database of Systematic Reviews, Issue 3. Art No.: CD005128. http:\/\/dx.doi.org\/10.1002\/14651858.CD005128.pub2 .","DOI":"10.1002\/14651858.CD005128.pub2"},{"key":"BFnrneph201359_CR84","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","volume":"78","author":"E Pillebout","year":"2010","unstructured":"Pillebout, E., Alberti, C., Guillevin, L., Ouslimani, A. & Thervet, E. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney Int. 78, 495\u2013502 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph201359_CR85","unstructured":"Floege, J. & Gr\u00f6ne, H. J. Recurrent IgA-nephropathy in the renal allograft: not a benign condition. Nephrol. Dial. Transplant. (in press)."},{"key":"BFnrneph201359_CR86","doi-asserted-by":"publisher","unstructured":"Moroni, G. et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfs472 .","DOI":"10.1093\/ndt\/gfs472"},{"key":"BFnrneph201359_CR87","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1093\/ndt\/gfr731","volume":"27","author":"PT Pham","year":"2012","unstructured":"Pham, P. T. & Pham, P. C. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol. Dial. Transplant. 27, 2965\u20132971 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201359_CR88","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/TP.0b013e3181705ad4","volume":"85","author":"F Berthoux","year":"2008","unstructured":"Berthoux, F. et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 85, 1505\u20131507 (2008).","journal-title":"Transplantation"},{"key":"BFnrneph201359_CR89","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","volume":"11","author":"P Clayton","year":"2011","unstructured":"Clayton, P., McDonald, S. & Chadban, S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am. J. Transplant. 11, 1645\u20131649 (2011).","journal-title":"Am. J. Transplant."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.59","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:42:43Z","timestamp":1684471363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,2]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFnrneph201359"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2013.59","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,2]]}}}